GW Pharmaceuticals Plc Top Insiders
GW Pharmaceuticals employs about 1.2 K people. The company is managed by 13 executives with a total tenure of roughly 145 years, averaging almost 11.0 years of service per executive, having 89.31 employees per reported executive. Assessment of GW Pharmaceuticals' management performance can provide insight into the firm performance.
Justin Gover CEO CEO, Director |
Geoffrey Guy Chairman Executive Chairman of the Board |
GWPH |
GW Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (3.55) % which means that it has lost $3.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.92) %, meaning that it created substantial loss on money invested by shareholders. GW Pharmaceuticals' management efficiency ratios could be used to measure how well GW Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.GW Pharmaceuticals Workforce Comparison
GW Pharmaceuticals Plc is one of the top stocks in number of employees category among related companies. The total workforce of Drug Manufacturers—General industry is currently estimated at about 244,156. GW Pharmaceuticals adds roughly 1,161 in number of employees claiming only tiny portion of equities under Drug Manufacturers—General industry.
The company has Profit Margin (PM) of (11.03) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (9.82) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $9.82. GW Pharmaceuticals Notable Stakeholders
A GW Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as GW Pharmaceuticals often face trade-offs trying to please all of them. GW Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting GW Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Justin Gover | CEO, Director | Profile | |
Geoffrey Guy | Executive Chairman of the Board | Profile | |
James Noble | Non-Executive Deputy Chairman of the Board, Senior Independent Director | Profile | |
William Waldegrave | Non-Executive Independent Director | Profile | |
Christopher Tovey | COO, Executive Director | Profile | |
Thomas Lynch | Non-Executive Independent Director | Profile | |
Catherine Mackey | Non-Executive Independent Director | Profile | |
Julian Gangolli | Executive Director | Profile | |
Alicia Secor | Non-Executive Independent Director | Profile | |
Adam George | CFO, Company Secretary, Director | Profile | |
Cabot Brown | Non-Executive Independent Director | Profile | |
Stephen Wright | Research & Development Director, Executive Director | Profile | |
Darren Cline | Chief Commercial Officer, U.S. | Profile |
GW Pharmaceuticals Workforce Analysis
Traditionally, organizations such as GW Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare GW Pharmaceuticals within its industry.GW Pharmaceuticals Manpower Efficiency
Return on GW Pharmaceuticals Manpower
Revenue Per Employee | 454.1K | |
Revenue Per Executive | 40.6M | |
Net Loss Per Employee | 50.1K | |
Net Loss Per Executive | 4.5M | |
Working Capital Per Employee | 318.3K | |
Working Capital Per Executive | 28.4M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in GWPH Stock
If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |